利福平
利福霉素
利福昔明
幽门螺杆菌
利福平
医学
抗生素
微生物学
药理学
克拉霉素
生物
内科学
作者
Lyudmila Boyanova,Rumyana Markovska,Petyo Hadzhiyski,Nayden Kandilarov,Ivan Mitov
出处
期刊:Future Microbiology
[Future Medicine]
日期:2020-08-01
卷期号:15 (12): 1185-1196
被引量:7
标识
DOI:10.2217/fmb-2020-0084
摘要
Helicobacter pylori eradication has become increasingly challenging. We focused on recent data about rifamycin resistance and rifamycin-containing regimens. Rifampin (rifampicin) resistance rates were <1–18.8% (often ≤7%), while those to rifabutin were 0–<4%. To detect rifabutin resistance by rifampin, 4 mg/l breakpoint was suggested. Eradication success by rifaximin-based regimens was disappointing (<62%), while that of rifabutin-containing regimens was 54.5–>96%, reaching >81% in four studies. Some newer rifamycin analogs like TNP-2092 need further investigation. Briefly, although rifabutin-based regimens carry a risk of adverse effects or increasing mycobacterial resistance, they may be a rational choice for some multidrug-resistant H. pylori strains and as a third-line eradication therapy. Bismuth addition to rifabutin-based therapy and combined rifabutin-containing capsules (Talicia) are promising treatment options.
科研通智能强力驱动
Strongly Powered by AbleSci AI